DEA Raises Adderall and Ritalin Quotas as the Shortage Drags On
DEA raised 2026 production quotas for amphetamine by 31-40% and methylphenidate by 19% on November 10, and proposed higher 2027 limits. Comments close Dec. 10.
Published
Key takeaways
- Effective now: a DEA final order dated November 10, 2026 raised this year's manufacturing limits for d,l-amphetamine by 30.6%, d-amphetamine by 40.3% and methylphenidate by 19.3%, after manufacturers asked for more quota to address shortages.
- Proposed for 2027: DEA wants to keep those higher levels and nudge amphetamine up again, and set lisdexamfetamine (Vyvanse) 22.5% above its January 2026 quota. Comments are due December 10, 2026.
- The shortage is still on: FDA's database still lists mixed amphetamine salts tablets, extended-release methylphenidate and lisdexamfetamine as current shortages, with 19 amphetamine salts presentations marked unavailable.
- Why it's your problem too: as a PMHNP you'll write these prescriptions, and a shortage turns into pharmacy calls, switches between formulations and patients going without.
Is there still an Adderall shortage? Yes. As of November 13, 2026, FDA's drug shortage database still lists mixed amphetamine salts tablets, the generic form of Adderall, as a current shortage, along with extended-release methylphenidate and lisdexamfetamine (Vyvanse). On November 10, the Drug Enforcement Administration responded with two Federal Register notices. The first, a final order effective that day, raised the 2026 production quotas for d,l-amphetamine by 30.6%, d-amphetamine by 40.3% and methylphenidate by 19.3%. The second proposes 2027 quotas that keep those higher levels, and it is open for public comment until December 10, 2026. Here's what DEA changed, why it says it acted, and what it means for the patients you'll be prescribing for as a psychiatric nurse practitioner.
What a DEA Production Quota Is
Every Schedule I and II controlled substance made in the United States is rationed by an aggregate production quota, or APQ. Section 306 of the Controlled Substances Act (21 U.S.C. 826) requires DEA to set, each year, the total amount of each drug's active ingredient that may be manufactured nationally to cover medical, scientific, research and industrial needs, lawful exports, and reserve stocks. DEA then divides that total into individual quotas for each registered manufacturer.
The quotas are written in grams of active ingredient, not in pills or prescriptions. "d-Amphetamine (for sale)" in a quota table means bulk dextroamphetamine headed into finished products. Most ADHD stimulants are Schedule II, including Adderall and its generics (a mix of amphetamine and dextroamphetamine salts), Vyvanse (lisdexamfetamine), Ritalin and Concerta (methylphenidate), and Focalin (dexmethylphenidate). So a quota that is set too low can limit how much medication reaches pharmacies, however many prescriptions are written.
The 2026 Increase: What Changed on November 10
The first notice is a final order titled "Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale)." DEA Administrator Terrance C. Cole signed it on November 4, and it took effect on publication, November 10, 2026. It changed four of the 2026 quotas DEA had set in January:
| Substance | 2026 before (million g) | 2026 now (million g) |
|---|---|---|
| d,l-amphetamine (Adderall and generics) | 24.23 | 31.65 (+30.6%) |
| d-amphetamine (for sale) (Adderall, Dexedrine and generics) | 26.45 | 37.11 (+40.3%) |
| methylphenidate (for sale) (Ritalin, Concerta and generics) | 58.28 | 69.50 (+19.3%) |
| hydromorphone (Dilaudid, an opioid) | 1.95 | 2.36 (+20.9%) |
DEA acted under a fast-track rule in the Controlled Substances Act. Under 21 U.S.C. 826(h), when a manufacturer asks for more quota for a Schedule II drug that is on FDA's shortage list, DEA has 30 days to review the request. If it finds an increase is needed to address the shortage, it must raise the quota. DEA said that deadline left no time for its usual comment period, so it published the 2026 change as a final order with no comments taken.
Why DEA Said It Raised Amphetamine
Two manufacturers of d,l-amphetamine asked for more quota on August 14 and August 24, 2026, and a d-amphetamine manufacturer asked on August 14. When DEA checked FDA's list, it found several manufacturers reporting a domestic shortage of amphetamine mixed salts tablets, some citing a "shortage of an active ingredient."
The demand numbers in the order are large. FDA predicted that domestic medical need in 2026 would rise 23.6% for d,l-amphetamine and 23.7% for d-amphetamine compared with what was observed in 2025. DEA wrote that "sufficient quota was granted to meet legitimate patient needs," but that more was needed "to allow for the adequate manufacturing of reserve stocks to start the next calendar year." It also pointed to companies developing new products: quota approved for product development so far in 2026 was up 173% for d,l-amphetamine and 32% for d-amphetamine compared with 2025.
Why DEA Said It Raised Methylphenidate
Manufacturers asked for more methylphenidate quota on July 31, August 1 and August 20, 2026. FDA's list showed shortages of methylphenidate tablets and film (the film is a skin patch), with companies citing "demand increase for the drug" or "discontinuation of the manufacture of the drug." FDA predicted domestic medical need for methylphenidate would rise 23.4% in 2026 over 2025. DEA also cited the International Narcotics Control Board: global methylphenidate stocks fell from 91.6 tons in 2023 to 80.6 tons in 2024, even though worldwide manufacturing hit its highest level on record.
The 2027 Proposal: Higher Again, and Open for Comment
The second notice, "Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances" for 2027, sets out next year's limits. For the ADHD stimulants, the proposed numbers are:
| Substance | 2026, set in January (million g) | 2027 proposed (million g) |
|---|---|---|
| d,l-amphetamine | 24.23 | 32.90 (+35.8%) |
| d-amphetamine (for sale) | 26.45 | 38.49 (+45.5%) |
| lisdexamfetamine | 51.29 | 62.83 (+22.5%) |
| methylphenidate (for sale) | 58.28 | 69.50 (+19.3%) |
| dexmethylphenidate (for sale) | 6.20 | 6.20 (no change) |
Compared with the 2026 levels as raised on November 10, the 2027 amphetamine proposals are another 3.9% (d,l-amphetamine) and 3.7% (d-amphetamine) higher, and methylphenidate stays where the November order put it.
DEA gave its reasons. FDA forecast a 3.93% average increase in domestic medical use of Schedule II stimulants in 2027, and it "raised concerns over drug shortages potentially related to the growth in telemedicine, supply chain issues, manufacturing and quality issues, and business decisions of manufacturers." For amphetamine, FDA estimated a 3.90% rise, but DEA's own projection from IQVIA prescription data and export data came out higher, at 6.98%. DEA said it set the amphetamine numbers "to address the growth in prescribing, export requirements, the global market, and to ensure sufficient inventory for domestic manufacturers."
Opioids are moving the other way. FDA predicted Schedule II opioid use would fall an average of 9.68% in 2027, and DEA proposed cuts for fentanyl, hydrocodone, hydromorphone, oxycodone and oxymorphone.
How Long the Stimulant Shortage Has Lasted
The FDA database tells the story in dates. The mixed amphetamine salts tablet shortage was first posted on October 12, 2022. Extended-release methylphenidate tablets were added on July 26, 2023, and lisdexamfetamine capsules and chewable tablets on July 14, 2023. All three are still marked "Current."
| FDA listing | Unavailable | Limited |
|---|---|---|
| Mixed amphetamine salts tablets (73 listed) | 19 | 14 |
| Methylphenidate ER tablets and film (38 listed) | 6 | 12 |
| Lisdexamfetamine capsules and chewables (108 listed) | 0 | 33 |
A "presentation" is one strength and package from one company, so the table counts products, not pharmacies. The remaining presentations in each row are marked available. The reasons manufacturers gave match what DEA described: shortage of an active ingredient for amphetamine salts, and rising demand or a discontinued product for methylphenidate. FDA's own note on the data says not to rely on it for medical decisions, and stock varies widely from one pharmacy to the next.
How to Comment on the 2027 Quotas
Anyone can comment on the 2027 proposal, including clinicians, students and patients. Comments go to Docket No. DEA-1730P through the federal eRulemaking portal at regulations.gov, and must be submitted electronically, or postmarked if mailed, by December 10, 2026. The portal stops taking comments at 11:59 p.m. Eastern that day. DEA says it may hold a public hearing based on what it receives, and will then publish a final order setting the 2027 quotas. In recent years, final quota orders have been published in December or early January: the 2026 quotas came out on January 5, 2026.
A useful comment is specific. If you work in a clinic or pharmacy, what you've seen (which drugs and strengths, how often, what patients did instead) is the kind of detail that is hard for DEA to get from sales data.
What the Quota Increase Doesn't Fix
A higher quota allows more to be made. It doesn't make it. Manufacturers still have to request and receive their individual quotas, produce the active ingredient, turn it into tablets and capsules, and ship them, and FDA's listings name causes that have nothing to do with DEA, such as manufacturing and quality problems and companies' business decisions. DEA's 2027 notice also says it now asks manufacturers and distributors to report to its ARCOS tracking system monthly instead of quarterly, and that 47% did so as of July 14, 2026. That is meant to help it see shortages sooner.
The quota also has nothing to do with whether a given clinician can prescribe these drugs. That is set by DEA registration and state law, covered in our guide to NP prescriptive authority by state. The separate federal question of prescribing controlled substances by telehealth has its own deadline: the current DEA telehealth extension runs out December 31, 2026.
What This Means for PMHNP Students
Stimulants will be part of your daily work if you treat ADHD, and a shortage changes what that work looks like. In practice it means a patient whose pharmacy can't fill the dose you wrote, a call to find another pharmacy, a switch between immediate- and extended-release forms or to a different stimulant, and, since Schedule II prescriptions can't be refilled, new prescriptions each time. Learn the equivalent doses between formulations and know your state's rules on transferring and partially filling Schedule II prescriptions. If ADHD care is where you want to work, start with whether a PMHNP can prescribe Adderall in your state and how NPs diagnose ADHD. Stimulant pharmacology is fair game on the board exam too; our PMHNP practice questions include it.
More PMHNP News
- HHS Finalizes HIPAA Privacy Rule Changes: 15-Day Records Deadline, No Change for Psychotherapy Notes Regulation · November 21, 2026
- Medicare Telehealth Extension Keeps the In-Person Rule Off Until 2028 Telehealth & Prescribing · November 5, 2026
- NHSC Students to Service Closes November 19 for 2027 Grads Financial Aid · November 5, 2026
Questions About This Story
Is there still an Adderall shortage in 2026?+
What did DEA change on November 10, 2026?+
Is there a Vyvanse shortage?+
When is the deadline to comment on the 2027 stimulant quotas?+
Does a bigger quota mean pharmacies will have Adderall right away?+
Sources
Primary sources are the agency, board, or organization that made the change. We read each one on the date shown.
- [1] DEA, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h), final order, Federal Register document 2026-22842 (November 10, 2026) Primary Verified November 14, 2026
- [2] DEA, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for 2027, Federal Register document 2026-22843, 91 FR 72566 (November 10, 2026) Primary Verified November 14, 2026
- [3] DEA, Established Aggregate Production Quotas for Schedule I and II Controlled Substances for 2026, Federal Register document 2025-24277, 91 FR 287 (January 5, 2026) Primary Verified November 14, 2026
- [4] FDA drug shortages data via openFDA: mixed amphetamine salts (data updated November 13, 2026) Primary Verified November 14, 2026
- [5] FDA drug shortages data via openFDA: methylphenidate (data updated November 13, 2026) Primary Verified November 14, 2026
- [6] FDA drug shortages data via openFDA: lisdexamfetamine (data updated November 13, 2026) Primary Verified November 14, 2026